Bevacizumab antiangiogenic therapy for glioblastoma

Neurology

Volumn 76, Issue 5, 2011, Pages 414-415

  Junck, Larry ^a  

^a UNIVERSITY OF MICHIGAN   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BEVACIZUMAB; CARBOPLATIN; CYCLOPHOSPHAMIDE; GADOLINIUM; IRINOTECAN; NITROSOUREA; PROCARBAZINE; TEMOZOLOMIDE;

ANTIANGIOGENIC THERAPY; BLOOD BRAIN BARRIER; CANCER GROWTH; CANCER INVASION; CANCER SURVIVAL; DRUG ACTIVITY; DRUG TREATMENT FAILURE; EDITORIAL; GLIOBLASTOMA; HUMAN; MEDICAL DECISION MAKING; NUCLEAR MAGNETIC RESONANCE IMAGING; PRIORITY JOURNAL; SURVIVAL TIME; TREATMENT DURATION;

EID: 79951471274     PISSN: 00283878     EISSN: 1526632X     Source Type: Journal    
DOI: 10.1212/WNL.0b013e31820a0d7e     Document Type: Editorial

References (10)

1. Folkman J, Klagsbrun M. Angiogenic factors. Science 1987;235:442-447. (Pubitemid 17009577)
2. Jain RK, di Tomaso E, Duda DG, Loeffler JS, Sorensen AG, Batchelor TT. Angiogenesis in brain tumours. Nat Rev Neurosci 2007;8:610-622. (Pubitemid 47093931)
3. Friedman HS, Prados MD, Wen PY, et al. Bevacizumab alone and in combination with irinotecan in recurrent gli-oblastoma. J Clin Oncol 2009;27:4733-4740.
4. Xu T, Chen J, Lu Y, Wolff JEA. Effects of bevacizumab plus irinotecan on response and survival in patients with recurrent malignant glioma: a systematic review and survival-gain analysis. BMC Cancer 2010;10:252.
5. Pope WB, Xia Q, Paton VE, et al. Patterns of progression in patients with recurrent glioblastoma treated with bevaci-zumab. Neurology 2011;76:432-437.
6. Lamszus K, Kunkel P, Westphal M. Invasion as limitation to anti-angiogenic glioma therapy. Acta Neurochir Suppl 2003;88:169-177.
7. Sakariassen PØ, Prestegarden L, Wang J, et al. Angiogenesis-independent tumor growth mediated by stem-like cancer cells. Proc Natl Acad Sci USA 2006;103: 16466-16471. (Pubitemid 44715219)
8. Pàez-Ribes M, Allen E, Hudock J, et al. Antiangiogenic therapy elicits malignant progression of tumors to increased local invasion and distant metastasis. Cancer Cell 2009;15:220-231.
9. Calabrese C, Poppleton H, Kocak M, et al. A perivascu-lar niche for brain tumor stem cells. Cancer Cell 2007; 11:69-82. (Pubitemid 46054518)
10. Kreisl TN, Kim L, Moore K, et al. Phase II trial of single-agent bevacizumab followed by bevacizumab plus irinote-can at tumor progression in recurrent glioblastoma. J Clin Oncol 2009;27:740-745.